Arizona State Retirement System Acquires 2,991 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Arizona State Retirement System raised its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 12.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,527 shares of the company’s stock after purchasing an additional 2,991 shares during the quarter. Arizona State Retirement System’s holdings in Sana Biotechnology were worth $112,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of SANA. TD Asset Management Inc boosted its stake in Sana Biotechnology by 100.0% in the 3rd quarter. TD Asset Management Inc now owns 362,652 shares of the company’s stock valued at $1,403,000 after buying an additional 181,326 shares in the last quarter. State of Michigan Retirement System acquired a new stake in shares of Sana Biotechnology in the 3rd quarter valued at $2,663,000. Principal Financial Group Inc. boosted its stake in shares of Sana Biotechnology by 13.1% in the 3rd quarter. Principal Financial Group Inc. now owns 42,664 shares of the company’s stock valued at $165,000 after purchasing an additional 4,928 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Sana Biotechnology in the 3rd quarter worth about $52,000. Finally, Barclays PLC increased its holdings in shares of Sana Biotechnology by 3.1% during the third quarter. Barclays PLC now owns 205,567 shares of the company’s stock worth $797,000 after buying an additional 6,096 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SANA has been the topic of several research reports. JMP Securities upped their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “market outperform” rating in a report on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Sana Biotechnology in a research note on Friday, March 1st.

Sana Biotechnology Price Performance

Shares of NASDAQ:SANA opened at $7.93 on Tuesday. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -5.39 and a beta of 1.61. The company has a 50 day moving average of $9.00 and a 200-day moving average of $6.00. Sana Biotechnology, Inc. has a one year low of $2.74 and a one year high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Thursday, February 29th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. During the same quarter last year, the business posted ($0.40) EPS. Equities research analysts anticipate that Sana Biotechnology, Inc. will post -1.02 earnings per share for the current year.

Insider Transactions at Sana Biotechnology

In related news, Director Robert Nelsen acquired 1,818,181 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was acquired at an average price of $5.50 per share, for a total transaction of $9,999,995.50. Following the completion of the acquisition, the director now owns 12,446,022 shares of the company’s stock, valued at approximately $68,453,121. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 34.90% of the stock is owned by corporate insiders.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.